Skip to content
2000
Volume 4, Issue 4
  • ISSN: 1874-4710
  • E-ISSN: 1874-4729

Abstract

The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crp/10.2174/1874471011104040295
2011-10-01
2025-10-05

  • From This Site

    /content/journals/crp/10.2174/1874471011104040295
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/content/journals/crp/10.2174/1874471011104040295
Loading

  • Article Type:     Research Article
Keyword(s): actinium-225; alpha emitter; Alpha emitting radionuclides; bismuth-213; clinical application; preclinical studies; radiolabeled peptide; RADIONUCLIDE GENERATORS; SPECT; Targeted alpha therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test